Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records

Nazario D. Rivera-Chaparro, Jessica Ericson, Huali Wu, P. Brian Smith, Reese H. Clark, Daniel K. Benjamin, Michael Cohen-Wolkowiez, Rachel G. Greenberg

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

Original languageEnglish (US)
Pages (from-to)e26-e28
JournalPediatric Infectious Disease Journal
Volume38
Issue number2
DOIs
StatePublished - Feb 1 2019

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records'. Together they form a unique fingerprint.

  • Cite this